Welcome to the e-CCO Library Archive!

Filter:
OP016

Treatment strategy during the first year after diagnosis in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort

Authors:

Z. Vegh*1, J. Burisch2, E.V. Tsianos3, L. Kupcinskas4, S. Turcan5, F. Magro6, 7, 8, A. Goldis9, V. Hernandez10, S. Bell11, P. Munkholm12, P. Lakatos1

1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2Hvidovre University Hospital, Gastrounit, Medical section, Hvidovre, Denmark, 3University of Ioannina, 1st Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, Ioannina, Greece, 4Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 5State University of Medicine and Pharmacy, Department of Gastroenterology, Chisinau, Moldova, Republic of, 6Hospital de São João, Department of Gastroenterology, Porto, Portugal, 7Oporto Medical School, Department of Pharmacology and Therapeutics, Porto, Portugal, 8University of Porto, 8 MedInUP - Center for Drug Discovery and Innovative Medicines, Porto, Portugal, 9University of Medicine ←Victor Babes→, Clinic of Gastroenterology, Timisoara, Romania, 10Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 11St Vincent's Hospital, Department of Gastroenterology, Melbourne, Victoria, Australia, 12Herlev University Hospital, Digestive Disease Center, Medical Section, Copenhagen, Denmark

OP017.

Cross-disease study determines extent of sharing of associated loci between five seronegative auto-inflammatory diseases

Authors:

D. Ellinghaus1, L. Jostins2, A. Cortes3, O. Andreassen4, Y. Wang5, S. Spain6, Inflammatory Bowel Disease Genetics Consortium7, International Genetics of Ankylosing Spondylitis Consortium8, The International PSC Study Group9, Collaborative Association Study of Psoriasis10, Psoriasis Association Genetics Extension11, Genetic Analysis of Psoriasis Consortium12, Wellcome Trust Case Control Consortium 213, J. Elder14, R. Trembath6, J. Barker6, T. Karlsen15, A. Dale16, D. McGovern17, S. Schreiber18, M. Brown19, J. Barrett2, M. Parkes20, A. Franke1, 1Christian-Albrechts-University Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 2Wellcome Trust Genome Campus, Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 3University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, 4University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 5Oslo University Hospital, Division of Mental Health and Addiction, Oslo, Norway, 6King's College London, Division of Genetics and Molecular Medicine, London, United Kingdom, 7on behalf of IIBDGC, Germany, 8on behalf of IGAS, Australia, 9on behalf of IPSCSG, Norway, 10on behalf of CASP, United Kingdom, 11on behalf of PAGE, United States, 12on behalf of GAPC, United Kingdom, 13on behalf of WTCCC2, United Kingdom, 14University of Michigan, Department of Dermatology, Ann Arbor, United States, 15Oslo University Hospital, Research Institute of Internal Medicine, Oslo, Norway, 16University of California, Department of Neurosciences, San Diego La Jolla, United States, 17Los Angeles, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, United States, 18University Hospital Schleswig-Holstein, Clinic of Internal Medicine I, Kiel, Germany, 19Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 20University of Cambridge, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom

OP017

Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab

Authors:

D. Laharie*1, A. Bourreille2, J. Branche3, M. Allez4, Y. Bouhnik5, J. Filippi6, F. Zerbib7, G. Savoye8, L. Vuitton9, J. Moreau10, A. Amiot11, J. Cosnes12, E. Ricart13, O. Dewit14, A. Lopez-Sanroman15, J.-L. Dupas16, F. Carbonnel17, G. Bommelaer18, B. Coffin19, X. Roblin20, G. Van Assche21, M. Esteve22, M. Farkkila23, J.P. Gisbert24, P. Marteau25, S. Nahon26, M. de Vos27, J.-Y. Mary28, E. Louis29

1Hopital Haut-Leveque, CHU de Bordeaux, Gastroenterologie, Pessac, France, 2CHU de Nantes, Department of Gastroenterology, Nantes, France, 3CHU de Lille, Department of Gastroenterology, Lille, France, 4Hopital Saint-Louis, Gastroenterologie, Paris, France, 5Hopital Beaujon, Gastroenterologie, Clichy, France, 6CHU de Nice, Gastroenterologie, Nice, France, 7CHU de Bordeaux, Gastroenterologie, Bordeaux, France, 8CHU de Rouen, Gastroenterologie, Rouen, France, 9CHU de Besancon, Gastroenterologie, Besancon, France, 10CHU de Toulouse, Gastroenterologie, Toulouse, France, 11Hopital Henri-Mondor, Gastroenterologie, Creteil, France, 12Hopital Saint-Antoine, Gastroenterologie, Paris, France, 13Hospital Clinic, Gastroenterology, Barcelona, Spain, 14UCL Saint-Luc, Gastroenterologie, Bruxelles, Belgium, 15Hospital ramon y Cajal, Gastroenterology, Madrid, Spain, 16CHU d'Amiens, Gastroenterologie, Amiens, France, 17Hopital du Kremlin-Bicetre, Gastroenterologie, Le Kremlin Bicetre, France, 18CHU de Clermont-Ferrand, Gastroenterologie, Clermont-Ferrand, France, 19Hopital Louis-Mourier, Gastroenterologie, Colombes, France, 20CHU de Saint-Etienne, Gastroenterologie, Saint-Etienne, France, 21University Hospital of Leuven, Gastroenterology, Leuven, Belgium, 22Hospital Universitari Mútua de Terrassa, Gastroenterology, Barcelona, Spain, 23Helsinki University Central Hospital, Gastroenterology, Helsinki, Finland, 24Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 25Hopital Lariboisiere, Gastroenterologie, Paris, France, 26Hopital de Montfermeil, Gastroenterologie, Montfermeil, France, 27Ghent University Hospital, Gastroenterology, Gent, Belgium, 28Hopital Saint-Louis, SBIM, Paris, France, 29Hopital Universitaire de Liege, Gastroenterologie, Liege, Belgium

OP018.

Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn's disease

Authors:

E. Quévrain1, M.-A. Maubert1, F. Chain2, R. Marquant3, P. Kharrat2, L. Carlier3, L. Bermudez2, B. Pigneur1, O. Lequin3, C. Bridonneau2, G. Thomas1, S. Lavielle3, J.-P. Grill1, G. Chassaing3, J. Masliah1, G. Trugnan1, R. Xavier4, P. Langella2, H. Sokol1, P. Seksik1, 1INSERM, UPMC, ERL U1057/UMR 7203, Paris, France, 2INRA, UMR 1319 Micalis, Jouy-en-Josas, France, 3UPMC, UMR 7203 UPMC, Paris, France, 4Harvard University, Center for Computational & Integrative Biology, Boston, United States

OP018

Prolonged Deep Remission of Ileocolonic Crohn's Disease following Autologous Haemopoetic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists

Authors:

C. Hawkey*1, M. Allez2, M. Clark1, M. Labopin3, J. Lindsay4, E. Ricart5, G. Rogler6, J. Satsangi7, D. Farge-Bancel8

1University of Nottingham, Nottingham Digestive Diseases Centre, Nottingham, United Kingdom, 2APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France, 3European Group for Blood & Marrow Transplantation, Chair-EBMT Statistical Committee, Paris, France, 4Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary Univesrity of London, Centre for Digestive Diseases, London, United Kingdom, 5Hospital Clinic, CIBER-EHD, Gastroenterology Department, Barcelona, Spain, 6University of Zurich, Division of Gastroenterology & Hepatology, Zurich, Switzerland, 7Western General Hospital, University of Edinburgh, Gastro-Intestinal Unit, Edinburgh, United Kingdom, 8APHP, Hopital Saint Louis, Internal Medicine & Vascular Disease Unit, Paris, France

OP019.

Hypoxia responsive elements methylation status governs adherent-invasive Escherichia coli-receptor CEACAM6 expression in Crohn's disease

Authors:

J. Denizot1, A. Agus1, A. Desrichard2, N. Uhrhammer2, A. Darfeuille-Michaud1, N. Barnich1, 1Université d'Auvergne, M2iSH, UMR INSERM/Université d'Auvergne U1071; Unité Sous Contrat Institut National de la Recherche Agronomique 2018, Clermont-Ferrand, France, 2Université d'Auvergne, Department of Oncogenetics, Department of Breast Oncology, Centre Jean Perrin, Clermont-Ferrand, France

OP019

Forty-Year Analysis of Colonoscopic Surveillance for Ulcerative Colitis Reveals Decreasing Risk of Interval and Advanced Cancer and Reducing Colectomy Rate for Dysplasia

Authors:

C.H.R. Choi*1, M. Rutter2, S. Thomas-Gibson3, J. Warusavitarne3, M. Moorghen3, B. Saunders3, T. Graham4, A. Hart3

1St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom, 2University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom, 3St Mark's Hospital, Department of IBD, Colorectal Surgery and Wolfson Unit of Endoscopy, London, United Kingdom, 4Queen Mary University of London, Centre for Tumour Biology, Barts Cancer Institute, London, United Kingdom

OP02. Identification of glycoprotein 2 as an immunomodulator of innate and adaptive immune responses
OP020.

16S rRNA gene pyrosequencing indicate that siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities

Authors:

C. Hedin1, C. van der Gast2, G. Rogers3, S. McCartney4, A.J. Stagg5, J.O. Lindsay6, K. Whelan1, 1King's College London, School of Medicine, Diabetes and Nutritional Sciences Division, London, United Kingdom, 2NERC, Centre for Ecology & Hydrology, Wallingford, Oxfordshire, United Kingdom, 3University of Queensland, Translational Research Institute, Immunity, Infection, and Inflammation Program, Mater Research Institute, Woolloongabba, Australia, 4University College London, Centre for Gastroenterology and Nutrition, London, United Kingdom, 5Blizard Institute, Queen Mary University of London, Centre for Immunology and Infectious Disease, London, United Kingdom, 6Barts and the London NHS Trust, Gastroenterology Division, London, United Kingdom

OP020

Patients with Inflammatory Bowel Disease and a history of cancer: The risk of cancer following exposure to immunosuppression

Authors:

J. Axelrad*1, O. Bernheim2, J.-F. Colombel2, S. Malerba3, A. Ananthakrishnan4, V. Yajnik4, G. Hoffman5, M. Agrawal6, D. Lukin7, A. Desai8, E. Mceachern9, B. Bosworth8, E. Scherl8, A. Reyes10, H. Zaidi11, P. Mudireddy12, D. DiCaprio13, K. Sultan11, B. Korelitz12, E. Wang14, R. Williams14, L. Chen15, S. Katz15, S. Itzkowitz2

1Icahn School of Medicine at Mount Sinai, Medicine, New York, United States, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States, 3Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States, 4Massachusetts General Hospital, Division of Gastroenterology, Boston, United States, 5Albert Einstein College of Medicine, Medicine, New York, United States, 6Montefiore Medical Center, Medicine, New York, United States, 7Montefiore Medical Center, Division of Gastroenterology and Liver Diseases, New York, United States, 8New York Presbyterian Weill Cornell Medical Center, Division of Gastroenterology, New York, United States, 9Weill Cornell Medical College, Medicine, New York, United States, 10North Shore- Long Island Jewish University Hospital, Medicine, Manhasset, United States, 11North Shore- Long Island Jewish University Hospital, Division of Gastroenterology, Manhasset, United States, 12North Shore- Long Island Jewish Lenox Hill Hospital, Division of Gastroenterology, New York, United States, 13North Shore- Long Island Jewish Lenox Hill Hospital, Medicine, New York, United States, 14NYU Langone Medical Center, Medicine, New York, United States, 15NYU Langone Medical Center, Division of Gastroenterology, New York, United States

OP021.

Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn's disease in the IMAgINE 1 trial

Authors:

A. Griffiths1, W. Crandall2, R. Colletti3, F. Ruemmele4, W.A. Faubion5, J. Hyams6, A. Lazar7, Y. Li8, S. Eichner8, R.B. Thakkar8, 1The Hospital for Sick Children, Department of Paediatrics, Toronto, ON, Canada, 2Nationwide Children's Hospital, Department of Gastroenterology/Nutrition, Columbus, United States, 3University of Vermont, Department of Pediatrics, Burlington, United States, 4Universite Sorbonne Paris-Cite, Hospital Necker-Enfants Malades, APHP, Paris, France, 5Mayo Clinic, Gastroenterology, Rochester, United States, 6Connecticut Children's Medical Center, Division of Digestive Diseases, Hartford, United States, 7AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany, 8AbbVie Inc, GPRD, North Chicago, United States

OP021

TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC)

Authors:

S. Vermeire*1, W. Sandborn2, S. Danese3, X. Hebuterne4, B. Salzberg5, M. Klopocka6, D. Tarabar7, T. Vanasek8, M. Gregus9, P. Hellstern10, J.-S. Kim11, M. Sparrow12, K.J. Gorelick13, A. Ahmad14, M. Hassan-Zahraee14, V. Pradhan14, F. Cataldi14, W. Reinisch15

1Leuven University Hospital, Leuven, Belgium, 2University of California San Diego, CA, United States, 3IBD-Division Gastroenterologia, Istituto Clinico Humanitas, Rozzano, Italy, 4Hospitall→Archet, Nice Cedex, France, 5Atlanta Gastroenterology Specialist, Suwanee, United States, 6University Hospital, Nicolaus Copernicus University, Torun Bydgoszcz, Poland, 7Military Medical Academy, Belgrade, Serbia, 8Hepato-gastroenterologie, Hradec Kralove, Czech Republic, 9Gastroenterologicke a hepatologicke, Nitra, Slovakia, 10Nature Coast Clinical Research, Inverness, Florida, United States, 11Seoul National University Hospital, Seoul, South Korea, 12Alfred Hospital of Melbourne, Melbourne, Australia, 13Pfizer Inc., Collegeville, United States, 14Pfizer Inc., Cambridge, United Kingdom, 15McMaster University Health Centre, Ontario, Canada

OP022.

Low microbial gene diversity and depletion of Akkermansia mucini­phila is associated with a relapsing course of ulcerative colitis

Authors:

F. Casellas1, N. Borruel1, C. Manichanh1, E. Varela1, M. Antolín1, A. Torrejón1, V. Robles1, F. Guarner1, on behalf of MetaHIT Consortium1,2, 1Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, 2MetaHIT Network, Partner Centres, Paris, France

OP022

Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study

Authors:

G. D'Haens*1, S. Lee2, D. Tarabar3, E. LOUIS4, M. Klopocka5, D.I. Park6, J. Claus7, X. Hébuterne8, W. Reinisch9, S. Schreiber10, K.J. Gorelick11, J. Cheng11, M. Hassan-Zahraee11, L. Brown12, A. Ahmad13, A. Banerjee13, F. Cataldi11, W. Sandborn14

1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University of Washington, Gastroenterology, Seattle, WA, United States, 3MMA, Gastroenterology, Belgrade, Serbia, 4University Hospital CHU of Liège, Gastroenterology, Liège, Belgium, 5Nicolaus Copernicus University in Toruń, Gastroenterology, Bydgoszcz, Poland, 6Kangbuk Samsung Hospital-Sungkyunkwan University, Gastroenterology, Seoul, South Korea, 7Universitätsklinikum Ulm, Gastroenterology, Ulm, Germany, 8CHU de Nice et Université de Nice Sophia-Antipolis, Gastroenterology, Nice, France, 9Medical University of Vienna, Internal Medicine/Gastroenterology, Vienna, Austria, 10University of Kiel, Gastroenterology, Kiel, Germany, 11Pfizer Inc., Gastroenterology, Cambridge, United States, 12Pfizer Inc., Gastroenterology, Cambridge, MA, United Kingdom, 13Pfizer Inc., Gastroenterology, Cambridge, MA, United States, 14Univeristy of California San Diego, Division of Gastroenterolgy, San Diego, United States

OP023.

Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study

Authors:

M.A. Kamm, P.P. De Cruz, E.K. Wright, A.L. Hamilton, K.J. Ritchie, E.O. Krejany, A. Gorelik, D. Liew, L. Prideaux, I.C. Lawrance, J.M. Andrews, P.A. Bampton, S.L. Jakobovits, T.H. Florin, P.R. Gibson, H.S. Debinski, A.S. Day, R.B. Gearry, F.A. Macrae, D. Samuel, R.W. Leong, I.J. Kronborg, G.L. Radford-Smith, W.S. Selby, M.J. Johnson, R.J. Woods, P.R. Elliott, S.J. Bell, S.J. Brown, W.R. Connell, P.V. Desmond, St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia

OP023

Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial.

Authors:

F. Carbonnel*1, J.F. Colombel2, J. Filippi3, K. Katsanos4, L. Peyrin-Biroulet5, M. Allez6, M. Nachury7, 8, G. Novacek9, S. Danese10, V. Abitbol11, F. Bossa12, J. Moreau13, G. Bommelaer14, A. Bourreille15, J.L. Dupas16, X. Roblin17, Y. Bouhnik18, W. Reinisch9, 19, M. Farkkila20, H. Brixi21, P. Seksik22, G. Malamut23, B. Coulibaly24, O. Dewit25, E. Louis26, D. Deplanque27, P. Michetti28, H. Sarter27, D. Laharie29

1APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 2Icahn Medical School of Medicine at Mount Sinai, , IBD center, New York, United States, 3University Hospital of Nice Archet 2, Gastroenterology, Nice, France, 4University of Ioannina School of Medical Sciences, Gastroenterology, Ioannina, Greece, 5University Hospital of Nancy, Gastroenterology, Nancy, France, 6Saint Louis Hospital APHP, Gastroenterology, Paris, France, 7University hospital of Lille, Gastroenterology, Lille, France, 8University hopsital of Besançon, Gastroenterology, Besançon, France, 9Medizinische Universität Wien, Gastroenterology, Vienna, Austria, 10Istituto Clinico Humanitas, Gastroenterology, Milano, Italy, 11Cochin University Hospital, Gastroenterology, Paris, France, 12Cancer Research and Cure Institute "Casa Sollievo Sofferenza", Gastroenterology, San Giovanni Rotondo, Italy, 13Rangueil University Hospital, Gastroenterology, Toulouse, France, 14University Hospital of Clermont Ferrand, Gastroenterology, Clermont Ferrand, France, 15Insitut des Maladies de l'Appareil Digestif, , Gastroenterology, Nantes, France, 16Amiens University Hospital, Gastroenterology, Amiens, France, 17University hospital of Saint Etienne, Gastroenterology, Saint Etienne, France, 18University hospital of Beaujon APHP, Gastroenterology, Clichy, France, 19Mc Master University , Gastroenterology, Hamilton, Canada, 20University Hospital of Helsinki, Gastroenterology, Helsinki, Finland, 21University hospital of Reims, Gastroenterology, Reims, France, 22University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France, 23Hôpital Européen Geroges Pompidou, APHP, Gastroenterology, Paris, France, 24General hospital of Avignon, Gastroenterology, Avignon, France, 25UCL Saint Luc, Gastroenterology, Bruxelles, Belgium, 26University hospital of Liège, Gastroenterology, Liège, Belgium, 27University hospital of Lille, Biostatistics and Clinical Research, Lille, France, 28Clinique de la Source, Gastroenterology, Lausanne, Switzerland, 29University hospital of Bordeaux, Gastroenterology, Bordeaux, France

OP024.

Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease

Authors:

R. Khanna1, G. Zou1,2, G. D'Haens1,3, P. Rutgeerts4, J.W. McDonald1, M. Daperno5, B.G. Feagan1,6, W.J. Sandborn1,7, E. Dubcenco1, M.K. Vandervoort1, A. Luo8, B.G. Levesque1,7, 1Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 2Western University, Department of Epidemiology and Biostatistics, London Ontario, Canada, 3University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 4University Hospital, Department of Gastroenterology, Leuven, Belgium, 5A.O. Ordine Mauriziano, Gastroenterology Division, Torino, Italy, 6Western University, Department of Epidemiology and Biostatistics, Department of Medicine, London Ontario, Canada, 7University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 8Bristol-Myers Squibb, Department, Princeton New Jersey, United States

OP024

A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study

Authors:

W. Sandborn*1, B. Feagan2, D. Wolf3, G. D'Haens4, S. Vermeire5, S. Hanauer6, S. Ghosh7, H. Smith8, M. Cravets8, P. Frohna8, S. Gujrathi8, A. Olson8

1University of California San Diego, Division of Gastroenterology, La Jolla, United States, 2University of Western Ontario, Department of Gastroenterology, London, Canada, 3Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States, 4Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 5University Hospital Leuven, Department of Gastroenterology, Leuven, Belgium, 6Northwestern University Feinberg School of Medicine, Digestive Health Center, Chicago, United States, 7University of Calgary, Department of Gastroenterology, Alberta, Canada, 8Receptos, Inc., Clinical Development, San Diego, United States

OP025

A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy

Authors:

B.E. Sands*1, J. Chen2, M. Penney2, P. Newbold2, R. Faggioni2, R. van der Merwe2, K. Patra2, P. Klekotka3, E. Pulkstenis2, J. Drappa2, R.A. Gasser, Jr.2

1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, 2MedImmune, Clinical Development, Gaithersburg, MD, United States, 3Amgen, Clinical Development, Thousand Oaks, CA, United States

OP026

Post-operative use of anti-TNFα agents in patients with Crohn's disease and risk of re-operation - a nationwide cohort study

Authors:

J. Kjeldsen*1, J. Nielsen2, M.D. Larsen2, N. Qvist3, B. Nørgaard2

1University of Southern Denmark, Department of Medical Gastroenterology, Odense University Hospital, and Research Unit of Gastroenterology, Odense , Denmark, 2University of Southern Denmark, Center for Clinical Epidemiology, Odense University Hospital, and Research Unit of Clinical Epidemiology, Institute of Clinical Research,, Odense, Denmark, 3University of Southern Denmark, Department of Surgery, Odense University Hospital, and Research Unit of Surgery, Institute of Clinical Research, Odense, Denmark

“Table: Standardized cancer incidence ratios of patients from the population based IBD-SL cohort, and of medication based sub groups